http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2014139666-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2121-00 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-22 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-232 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-11 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0053 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-232 |
| filingDate | 2013-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2016-04-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2014139666-A |
| titleOfInvention | DIAGRAMS OF TREATMENT AND METHODS OF IMPROVING THE VISUAL FUNCTION IN VISION DISORDERS CONNECTED WITH ENDOGENOUS RETINOID DEFICIENCY |
| abstract | 1. A method of improving visual function in a subject having a deficiency of endogenously produced 11-cis retinal, comprising: a. administering a first therapeutic dose of a synthetic retinal derivative to a subject in need thereof, wherein the first therapeutic dose is administered in divided dose form over a period of about 2 to about 7 days; b. providing a rest period of from about 7 to about 28 days; ex. administering a second therapeutic dose of a synthetic retinal derivative to said subject at the end of the rest period. 2. The method of claim 1, wherein the subject has retinitis pigmentosa (RP). The method of claim 2, wherein the subject has a moderate to severe RP. The method of claim 2, wherein the subject has a light RP.5. The method of claim 2, wherein the subject has an early-onset RP or juvenile RP. The method of claim 1, wherein the subject has Leber's congenital amaurosis (LCA). The method of claim 1, wherein the subject has a mutation of the LRAT gene. The method of claim 1, wherein the subject has a RPE65.9 gene mutation. The method of claim 1, wherein the synthetic retinal derivative provides for the replacement of an endogenously produced 11-cis retinal. The method of claim 1, wherein the method further comprises repeating steps b and one or more times. The method of claim 1, wherein the first therapeutic dose is administered in the form of: (a) a divided dose over a period of 7 days; (b) a divided dose over a period of 5 days; or (c) a divided dose over a period of 6 days, 4 days, 3 days or 2 days. 12. The method of claim 1, wherein the rest period is from about 7 days to about 21 days. The method of claim 12, wherein the rest period is about 21 days. The method of claim 12, wherein the rest period was |
| priorityDate | 2012-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 84.